Ascendis Pharma AS

Stock Chart, Company Information, and Scan Results

$261.58(as of Jun 25, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ascendis Pharma AS Company Information, Fundamentals, and Technical Indicators

Stock Price$261.58
Ticker SymbolASND
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees1,189
CountyUSA
Market Cap$15,953.9M
EBIDTA-10.2M
10-Day Moving Average231.63
P/E Ratio33.32
20-Day Moving Average224.41
Forward P/E Ratio14.75
50-Day Moving Average231.49
Earnings per Share8.65
200-Day Moving Average218.62
Profit Margin255.21%
RSI71.26
Shares Outstanding65.6M
ATR11.09
52-Week High250.74
Volume2,653,729
52-Week Low160.86
Most Recent Support Level222.82
Book Value488.5M
Most Recent Resistance Level224.11
P/B Ratio34.55
Upper Keltner249.35
P/S Ratio19.46
Lower Keltner199.47
Debt-to-Equity Ratio249.35
Next Earnings Date08/05/2026
Cash Surplus-554.5M
Next Ex-Dividend DateUnknown

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma AS In Our Stock Scanner

As of Jun 26, 2026
As of ---
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.